|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The KRAS proto-oncogene is mutated in >90% of PDAC.
|
20179210 |
2010 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We developed an approach to statistically humanize the mouse networks with data from human cancer and identified genes within the humanized CRC and PDAC networks synthetically lethal with mutant KRAS.
|
31521603 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
Obesity driven by chronic consumption of high-fat diet (HFD) is a major risk factor for oncogenic KRAS-mediated pancreatic ductal adenocarcinoma (PDAC).
|
30819189 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we examine the central part that KRAS plays in the biology of PDAC, and how the timing and location of Hh and Wnt-β-catenin signalling dictate the specification and oncogenic properties of PDAC.
|
20814421 |
2010 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In pancreatic ductal adenocarcinoma (PDAC), mutant KRAS stimulates the translation initiation factor eIF5A and upregulates the focal adhesion kinase PEAK1, which transmits integrin and growth factor signals mediated by the tumor microenvironment.
|
28381547 |
2017 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While CDK4/6 represents a downstream target of both KRAS mutation and loss of the CDKN2A tumor suppressor in PDAC, clinical and preclinical studies indicate that pharmacological CDK4/6 inhibitors are only modestly effective.
|
31745297 |
2020 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, we provide the first evidence that miR-873 acts as a tumor suppressor by targeting KRAS and that miR-873-based gene therapy may be a therapeutic strategy in PDAC and TNBC.
|
30654191 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the current study, we demonstrate that ISG15 pathway knockdown reverses the KRAS-associated phenotypes of PDAC cells such as increased proliferation and colony formation.
|
31709456 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Circulating cell-free DNA (cfDNA) is a promising resource to detect molecular characteristics of tumors, supporting the concept of "liquid biopsy".We determined the mutational status of KRAS in plasma cfDNA using multiplex droplet digital PCR in 259 patients with PDAC, retrospectively.
|
27753011 |
2016 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
KRAS/GNAS mutations and immunohistochemical (IHC) expression of p53 and p16/CDKN2A were assessed in both IPMN and distinct PDAC.
|
26646266 |
2016 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As demonstrated by either cytology or finding of a KRAS mutation, CTC were detected in 18 of 21 patients (86 %) with proven PDAC: 8 out of 10 patients (80 %) with early stage (UICC IIA/IIB) and 10 out of 11 (91 %) with late stage (UICC III/IV) disease.
|
26684803 |
2016 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, miR-217 expression was observed to be negatively correlated with KRAS protein expression in PDAC cell lines.
|
20675343 |
2010 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Knockdown or overexpression of KRAS in PDAC cell lines robustly increased or decreased, respectively, RKIP protein and mRNA levels.
|
29315556 |
2018 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The most common gene mutations associated with PDAC include KRas2, p16, TP53, and Smad4.
|
28067794 |
2017 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in K-Ras are found in nearly all cases, but K-Ras mutations alone are not sufficient for the development of PDAC.
|
22900040 |
2012 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Pancreatic juice from PDAC patients is rich in KRAS mutations often not seen in the primary tumor and possibly reflecting precancerous lesions in other regions of the pancreas.
|
30611220 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the context of pancreatic ductal adenocarcinoma (PDAC), oncogenic KRAS induces benign pancreatic intraepithelial neoplasias (PanINs), which exhibit features of oncogene-induced senescence.
|
30614183 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutations play a critical role as they are involved in both initiating and maintaining PDAC development.
|
31341034 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The authors also discuss other targets relevant to PDAC including those downstream of mutated KRas, such as MAPK kinase and phosphatidylinositol 3-kinase.
|
24673265 |
2014 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a meta-analysis for the diagnostic utility of the four major altered genes in PDAC (KRAS, CDKN2A/p16, TP53, and SMAD4/DPC4), telomerase activity, and a combination assay using PJ samples.
|
26899542 |
2017 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of this study demonstrate that cftDNA <sup>mut</sup>KRAS changes are associated with tumor response to chemotherapy and support the evidence that <sup>mut</sup>KRAS in plasma may be used as a new marker for monitoring treatment outcome and disease progression in PDAC.
|
28801547 |
2017 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
The newly discovered KRAS-ILK-hnRNP A1 regulatory loop is discussed, emphasizing its potential as a therapeutic target for PDAC-specific molecules.
|
27888145 |
2017 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutations are present in >90% of PDAC and are connected to many signaling pathways through its oncogenic cascade, including extracellular regulated kinase (ERK) and MYC.
|
30228208 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
K-Ras mutations are a hallmark of human pancreatic adenocarcinoma (PDAC) and epithelial-mesenchymal-transition (EMT) is a driver of progression.
|
29308316 |
2018 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.100 |
Biomarker
|
disease |
BEFREE |
KRAS gene is frequently mutated in pancreatic ductal adenocarcinoma (PDAC) (up to 90%), and mutation analysis of KRAS has been proposed as diagnostic biomarker of PDAC.
|
28450086 |
2017 |